COMP <GO>
BCO vs TMO // ENTERPRISE SCALE & MARKET CAP
Brinks Company (The) (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: BCO 6
— TMO 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $102.71 (+0.51%) • MKT CAP: $4.21B
market-cap
$4.21B
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCO VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCO | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.80% | 41.00% | -15.20 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 19.60% | 9.30% | +10.30 | BCO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 8.3x | 30.4x | -22.10 | BCO | /valuation <GO> |
| Free Cash Flow Yield | 0.58% | 2.40% | -1.82 | TMO | /fcf-yield <GO> |
| Operating Margin | 11.10% | 17.40% | -6.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 3.80% | 15.10% | -11.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 3.90% | +1.10 | BCO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.00% | 0.24% | +0.76 | BCO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.58 | 4.50 | -2.92 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 59.1 | -14.81 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | BCO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.6x | 36.3x | -16.70 | BCO | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $4.21B | $262.22B | -$258.01B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCO REV | TMO REV | BCO GROSS % | TMO GROSS % | BCO FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.26B | $44.56B | 25.8% | 44.0% | $20.6M | $6.29B |
| FY 2024 | $5.01B | $42.88B | 25.3% | 44.0% | -$40.1M | $7.27B |
| FY 2023 | $4.87B | $42.86B | 44.0% | 44.0% | -$121.1M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCO // BETA 1.00
TMO // BETA 0.94